Introduction
Bladder cancer care continues to represent a significant financial burden on the population and healthcare system of the United States with more than 68 800 new diagnoses and 14 000 deaths estimated for 2008 [1] . Therapeutic advances have occurred in bladder cancer care, but these have come at an increased cost -to payers, providers, and patients. In 2006, the United States spent over $2.1 trillion, or $7026 per person, on providing healthcare to its citizens, and medical technology contributed significantly to these expenses [2] . Given the aging of the population and the continued technological advances likely to occur over the next decade, such as new urinary markers for bladder cancer, improved endoscopy, and the evolving role of minimally invasive surgery, managing patients with bladder cancer will likely become much more costly than it is today. At the same time, each patient's out-of-pocket costs will likely increase. Thus, there will be growing pressures to contain costs and more efficiently manage care and societal resources. Economic studies in bladder cancer will allow us to know how the money is currently spent and help determine more effective ways to allocate resources.
Background
Cancer care economics examines the benefits and limitations of a given treatment, or constellation of treatments, in a different manner than traditional clinical outcomes research. The following section provides a primer on costeffectiveness and health preference metrics.
Cost-effectiveness evaluation design
Cost-effectiveness assessment is a comparative analysis of two or more alternative interventions in terms of both their health effects and cost [3 ,4] . Hence, cost-effective evaluations can help distinguish between the interventions that are less costly while providing more health benefit than the current standard (and, therefore, should be preferred over the standard treatment) and a treatment that is more effective but also more costly than the currently used alternative (and, hence, requires a more detailed analysis of additional cost per unit benefit).
Cost and outcomes data may come from a single source (e.g., a clinical-economic trial) or be combined from multiple sources by a decision analytic model. There are several key concepts that make designing and interpreting economic evaluations nontrivial and different from other practice-based evidence. These include, multiple possible study perspectives, such as that of the 'patient', 'third-party payer', 'provider', or 'society' [6]; difficulty collecting data on healthcare utilization that come from multiple sources [7] ; discrepancies between costs, charges, and reimbursements in healthcare [8, 9] ; calculating lost patient productivity and other nonmedical costs [3 ,10] ; presenting the results of costeffectiveness analyses [11] [12] [13] , (Figs 1 and 2) [5]; and evaluating patient health preferences as one potential outcome measure. Although most of these issues are explained well in the literature, we will discuss the last point in greater detail because the trade-off between costs and outcomes is an essential concept in costeffectiveness research and health preferences are the recommended outcome for economic evaluations [3 ] .
534 Bladder cancer The cost-effectiveness acceptability curve represents the set of probabilities that the new intervention is cost-effective compared to the standard of care for a range of values of societal willing-to-pay for an incremental gain in health [10] [11] [12] . Reproduced with permission from [5] . CE, costeffectiveness; QALY, quality-adjusted life year.
In cost-effectiveness studies, the gold standard is to report results as cost per quality-adjusted life year (QALY) gained. Very little is known about HRQOL associated with the states and treatment of bladder cancer. The Tufts costeffectiveness registry provides a comprehensive list of all studies addressing health utility or cost-effectiveness for individuals, groups, interventions, and programs [17 ] . For the utility of bladder cancer, they reported one study [18] that used data on health preferences for health states associated with bladder cancer (0.89 for women, 0.91 for men) using the national data from the Netherlands [19, 20] .
Although earlier studies assumed that bladder preservation was associated with better HRQOL compared with radical cystectomy, recent improvements in surgical techniques have significantly improved HRQOL after cystectomy and reduced the potential incentives for performing extensive, morbid, and risky bladder-sparing procedures [21 ,22,23] .
Moreover, the comprehensive review done by Porter et al. [24, 25] that describes the landscape of HRQOL research in patients who have undergone cystectomy and urinary diversion demonstrated that although much work has been done on the subject, there is no evidence to suggest a differential impact on a patient's quality of life based on the type of urinary diversion performed. However, most of the publications they reviewed were hindered by methodological limitations such as the heavy use of retrospective studies based at academic centers and the limited number of diseasespecific validated survey instruments.
In summary, HRQOL provides an important complementary approach to the more frequently discussed endpoints of overall and disease-specific mortality and can play a significant role in a patient's ability to make an informed choice about competing but effective courses of treatment.
Study findings
We conducted a systematic review of the literature on the economics of bladder cancer using Medline, the UK National Health System (NHS) [26 -29 ] . All agree on the need for meticulous attention to surgical technique during transurethral resection of bladder tumors (TURBTs), as the depth of tumor invasion is both a critical treatment and prognostic factor. Careful follow-up is required for high-grade nonmuscle invasive tumors and carcinoma in situ (CIS) due to their tendency for progression. Cystectomy is the gold standard for muscle-invasive disease [21 ] . Despite these similarities, there are several areas that require further attention. In the following section, we present current bladder cancer treatment, surveillance, and prevention interventions based on available evidence of their costeffectiveness.
Cost-effective but underused
Although several studies have indicated that bladder cancer is a common disease associated with substantial economic burden for patients and society, the evidence of cost-effectiveness of bladder cancer interventions is limited and of insufficient quality [30] . In this article, we review several bladder cancer interventions that have been established as cost-effective and should be, but are generally not, adopted for wider use.
The use of a single dose of intravesical chemotherapy postTURBT has been shown to reduce the risk of bladder cancer recurrence. The AUA, EUA, and NCCN discuss the benefits and limitations of this practice in their respective guidelines, but differing economic arguments are put forward by the AUA and EUA to support their positions. The AUA recommends the practice in the setting of known low-grade, nonmuscle invasive disease but made the use of single dose of intravesical chemotherapy optional if the presence of malignancy was suspected but not pathologically proven because of 'potential cost issues, side-effects, and patient preference' [26 ] . Unfortunately, the potential cost issues were neither elaborated nor were references cited. Presumably, these costs would include the price of the chemotherapy, increased time spent in the postanesthesia recovery unit (or other ambulatory surgical care area), increased nursing care, and proper disposal of the intravesical agent. The EUA, in contrast, uses a costeffective analysis based on the number of patients needed to be treated with intravesical chemotherapy to prevent a single bladder cancer recurrence (8.5 patients), and that the costs associated with 8.5 instillations of postTURBT intravesical chemotherapy are cheaper than one repeat TURBT for recurrence, to support the wide use of this practice [31] . Moreover, Madeb et al. [32] have demonstrated that use of a single dose of intravesical chemotherapy postTURBT would result in a cost savings of $689.39 (12%) per patient treated with TURBT and intravesical chemotherapy compared with those who did not receive same day instillation. Nationally, this would reflect a $24.8 million cost saving per year.
Among other ways of reducing costs associated with bladder cancer is to reduce the rate of postcystectomy complications [33, 34] . Primary postoperative complications have the most significant impact on the health outcomes and cost of care. Furthermore, high-risk inpatient bladder cancer procedures such as cystectomy were shown to be influenced more by systems of care (e.g., availability of nursing staff, expensive equipment, and multidisciplinary teams of providers) and in general were less expensive to perform in highvolume centers [35] . At the same time, lower risk procedures such as TURBT, which are not influenced by systems of care, may be more cost-effective when performed in ambulatory surgical units or at community centers.
Prevention of bladder cancer by reducing the rate of cigarette smoking in the population is another potentially highly cost efficient but underused strategy for reducing the cost associated with bladder cancer. Smoking has been long shown to be associated with increased risk for bladder cancer [36] [37] [38] . Numerous studies have demonstrated that the costs of smoking cessation interventions are relatively low compared with the resulting gains of avoided morbidity, mortality, and economic burden of smoking-related illnesses, including costs associated with bladder cancer [18] .
Potentially overused and not cost-effective
Although all three bladder cancer guidelines discuss the importance of posttreatment surveillance across all disease stages, a single agreed upon strategy has not yet been established. Most components of follow-up visits are not very costly; office visit with interval history and physical exam, urinary cytology, flexible cystoscopy, blood chemistries, and so on. Imaging, however, which is often done through computed tomography (CT), has both financial costs and a small but real risk of secondary malignancy from the ionizing radiation it uses. Brenner and Hall [39 ] outlined the seldom considered risks of CT scans in their recent review. Increased risk of cancer due to the ionizing effects of radiation from CT scans occurs after a dose of 30-90 mSv, which is accumulated in only two or three scans. To place this in context, scans performed to evaluate causes of hematura (CT urography) consist of at least three scans (noncontrast, contrast, delayed images), whereas postcystectomy studies will image both the abdomen and pelvis and are performed at varying frequencies based on stage of disease, postoperative complications, and other clinical indicators. As the majority of patients treated for bladder cancer are in their seventh decade and older, it is unlikely that they will live through the decades-long latency period of secondary tumors that may have been caused by exposure to CT radiation. However, developing consensus guidelines about the use of imaging for bladder cancer surveillance is an attainable goal that could help curb the costs of imaging associated with bladder cancer and establish potentially safer patient care practices.
Need cost-effectiveness evaluation
The AUA, EUA, and NCCN guidelines all recognize pelvic lymphadenectomy as a fundamental component of radical cystectomy. Recent work by Dhar et al. [40 ] comparing outcomes after radical cystectomy in patients who underwent pelvic lymph node dissection (PLND) with standard versus extended resection templates likely represents a paradigm shift for the surgical management of invasive bladder cancer. The authors found that performing an extended PLND improved pathologic staging and increased the survival for patients with node-negative, node-positive, and extravesical disease. Although this study was limited by its retrospective nature and limited generalizability to nonacademic centers, it demonstrates that the extent and thoroughness of PLND is a significant determinant of bladder cancer outcomes. This study did not comment on differences in cost or complication rates, but an extended lymphadenectomy is unlikely to drastically prolong operative times or increase morbidity (although approximately 1/3 to 1/4 of patients who undergo radical cystectomy experience some type of complication). The renewed importance of PLND as a prognostic and therapeutic tool raises the bar for laparoscopic and robotic approaches as they attempt to demonstrate oncologic and economic efficacy in the management of muscle-invasive bladder cancer [41 ] .
Several new bladder cancer diagnostic tests have been recently approved and many more are undergoing development and investigation [42] . However, because the Food and Drug Administration (FDA) approval process does not require any proof of cost-effectiveness, new tests almost always mean higher costs of care [42] .
To address this problem, Svatek et al. [43] have demonstrated that screening populations at high risk for bladder cancer could be substantially more cost-effective than universal screening. Investigational technologies that have not yet been incorporated into treatment guidelines, such as fluorescence cystoscopy [44 ] and urine biomarkers [45 ] , may facilitate the diagnosis, treatment, and follow-up of patients with bladder cancer but their economic impact will not be known until they receive FDA approval and fully enter the healthcare market.
Conclusion
Economic information can inform decisions about healthcare coverage, access, and cost, which can ultimately lead to improvements in quality of care. In addition, economic information can provide cost predictions so that providers can be paid appropriate rates for caring for groups of people including patients with bladder cancer. Patient advocacy groups, lobbyists, and researchers often use economic information (i.e., estimates of economic burden of disease) to support or further their cause of obtaining more funding for social programs and research.
One of the most common purposes for the economic evaluation of bladder cancer care is to help determine the relative value of new or expensive interventions compared with the standard of care and to improve the efficiency with which healthcare services are delivered. For example, bladder preservation for muscle-invasive bladder cancer using aggressive TURBT, chemotherapy, and external beam radiation therapy is a costly upfront investment in terms of time and money, and many would rightly ask if this investment is worth the long-term improvements in health gained [21 ] . Another example is robotic surgery, which requires a significant capital investment in equipment and time to train operative and support staff while the procedure is reimbursed at the same rate as standard surgery. The methods of costeffectiveness research provide the analytic framework to make such assessments.
Listed below are suggestions for improving the use of economic information in bladder cancer care, by improving the methodology for conducting economic assessments of bladder cancer interventions and by encouraging collaborative partnerships between urologists, health economists, quality of life researchers, and health policy researchers:
(1) Become familiar with the study designs and methods of cost-effectiveness research, (2) Recognize that the evidence from cost-effectiveness research is different from that of clinical trials but can be useful to inform clinical and health policy decision-making, (3) Research on the most reliable and accurate ways to collect resource use and measure the costs of bladder cancer care, (4) More natural history studies to serve as the clinical backbone of lifetime cost estimates of bladder cancer, (5) More Phase III and IV clinical trials of bladder cancer interventions should include an economic component, (6) Incorporate information about cost-effectiveness into bladder cancer clinical practice guidelines and practice parameters.
Although necessary for rational decision-making, obtaining more information about the economic values of bladder cancer interventions comes at a cost (e.g., costs of additional data collection, medical claims, patient interviews, designing and conducting new clinicaleconomic trials, data analysis, and information dissemination to providers and patients). Ideally, we would strive to evaluate the cost-effectiveness of all commonly used bladder cancer interventions and procedures aiming to use only the ones that are both clinically and economically advantageous; but conducting these evaluations would also contribute to the cost of healthcare.
In time, economic evaluations may play a greater role in the development and promulgation of bladder cancer treatment guidelines, such as those recently released by the AUA, EUA, and NCCN and similar to the approach used for developing clinical guidelines in other countries with national health systems (e.g., the United Kingdom, Canada, Australia, Israel and so on) [46] [47] [48] .
